
	As of
	December 31, 2024		December 31, 2023
Cash and cash equivalents	$	2,874	$	2,494
Short-term restricted cash	16		10
Total Cash, cash equivalents, and restricted cash as presented in the Consolidated Statements of Financial Position	2,889		2,504
Long-term restricted cash(1)	3		2
Total Cash, cash equivalents, and restricted cash as presented in the Consolidated and Combined Statements of Cash Flows	$	2,893	$	2,506

Certain inventory items are long-term in nature and therefore have been recognized within All other non-current assets in the Consolidated Statements of Financial Position and are not reflected in the table above. See the supplemental table “All Other Current and Non-Current Assets” for further information.

PROPERTY, PLANT, AND EQUIPMENT – NET.


	As of
	December 31, 2024		December 31, 2023
Land and improvements	$	66	$	70
Buildings, structures, and related equipment	1,943		1,956
Machinery and equipment	2,705		2,617
Leasehold improvements and manufacturing plants under construction	553		565
Total property, plant, and equipment, at original cost	5,267		5,208
Accumulated depreciation	(3,080)		(3,064)
Right-of-use operating lease assets, net of amortization(1)	364		356
Property, plant, and equipment – net	$	2,550	$	2,500

Depreciation related to Property, plant, and equipment – net, exclusive of ROU operating lease assets, was $268 million, $248 million, and $228 million for the years ended December 31, 2024, 2023, and 2022, respectively.


All Other Current and Non-Current Assets	As of
	December 31, 2024		December 31, 2023
Prepaid expenses and deferred costs	$	188	$	147
Financing receivables – net	90		97
Derivative instruments	123		84
Tax receivables	115		53
Other	13		8
All other current assets	$	529	$	389

Prepaid pension asset	$	657	$	716
Equity method and other investments	373		357
Financing receivables – net	183		178
Long-term receivables – net	142		124
Inventories	139		147
Contract and other deferred assets	208		168
Other(1)	248		191
All other non-current assets	$	1,950	$	1,881

(1) Non-current Other primarily consists of indemnity assets associated with separation agreements with GE, capitalized costs associated with cloud computing arrangements, tax receivables, and derivative instruments.


All Other Current and Non-Current Liabilities	As of
	December 31, 2024		December 31, 2023
Sales allowances and related liabilities	$	242	$	228
Income and indirect tax liabilities including uncertain tax positions	279		260
Product warranties	168		192
Accrued freight and utilities	163		132
Operating lease liabilities	115		110
Derivative instruments(1)	90		128
Interest payable on borrowings	92		87
Environmental and asset retirement obligations	17		21
Other(2)	379		335
All other current liabilities	$	1,545	$	1,493

Contract liabilities	$	686	$	705
Operating lease liabilities	270		273
Environmental and asset retirement obligations	291		265
Income and indirect tax liabilities including uncertain tax positions	237		208
Derivative instruments	64		136
Finance lease obligations	40		38
Sales allowances and related liabilities	23		27
Other(3)	184		225
All other non-current liabilities	$	1,796	$	1,877

(3) Non-current Other primarily consists of miscellaneous accrued costs, indemnity liabilities associated with separation agreements with GE, and contingent consideration liabilities.


		Equity method investment balance				Equity method income (loss)
As of December 31	Ownership Percentage	2024		2023		2024		2023		2022
Nihon Medi-Physics Co., Ltd(1)	50%	$	139	$	150	$	10	$	10	$	16
Other		24		20		(2)		1		(3)
Total		$	163	$	170	$	8	$	11	$	13

(1) In the fourth quarter of 2024, GE HealthCare announced an agreement to acquire the remaining ownership interest of NMP. See Note 8, “Acquisitions, Goodwill, and Other Intangible Assets” for more information.

A rollforward of our outstanding obligations confirmed and paid under the supply chain finance programs, which are included within Accounts Payable in the Consolidated Statements of Financial Position, is presented below.


	For the year ended December 31
	2024
Confirmed obligations outstanding at beginning of period	$	365
Invoices confirmed during the year	886
Confirmed invoices paid during the year	(855)
Foreign exchange and other	(2)
Confirmed obligations outstanding at end of period	$	394

In October 2023, we entered into a Collaboration and License Agreement with Novo Nordisk (“Novo”) to pursue a collaboration on the development, regulatory approval, and commercialization of an ultrasound therapy. Under the terms of this agreement, in return for providing development activities associated with the development of the underlying ultrasound device to deliver Novo’s clinical therapies, we received an upfront nonrefundable payment with the potential for additional nonrefundable payments through 2027. We recognize the nonrefundable payments as an offset to R&D expense as we perform activities contemplated under this agreement. These nonrefundable payments are not material. We may also receive future payments based on the achievement of certain development milestones and regulatory approvals associated with the ultrasound therapy.

The Company has noncontrolling interests with redemption features. These redemption features, such as put options, could require the Company to purchase the noncontrolling interests upon the occurrence of certain events. All noncontrolling interests with redemption features that are not solely within our control are recognized within the Consolidated Statements of Financial Position between liabilities and equity. Redeemable noncontrolling interests are initially recorded at the issuance date fair value. Those that are currently redeemable, or probable of becoming redeemable, are subsequently adjusted to the greater of current redemption value or initial carrying value.


	For the years ended December 31
	2024		2023		2022
Balance at beginning of period	$	165	$	230	$	220
Net income attributable to redeemable noncontrolling interests	50		41		47
Redemption value adjustments(1)	—		183		—
Distributions to and exercise of redeemable noncontrolling interests and other(2)	(28)		(289)		(37)
Balance at end of period	$	188	$	165	$	230

(1) As of January 3, 2023, certain redeemable noncontrolling interests were probable of becoming redeemable due to the change of control that occurred upon consummation of the Spin-Off. As a result, these redeemable noncontrolling interests were remeasured to their current redemption value. The remeasurement was accounted for as a deemed preferred stock dividend of redeemable noncontrolling interest and recorded as an adjustment to Retained earnings in the Consolidated Statements of Financial Position.

(2) In the first quarter of 2023, the redeemable noncontrolling interest holder exercised its option redemption provision. The redemption amount of $211 million was paid in the second quarter of 2023.


	For the years ended December 31
		2024		2023		2022
Net financing income and investment income (loss)		$	(1)	$	26	$	(9)
Equity method income (loss)		8		11		13
Change in fair value of assumed obligations		(32)		(32)		—
Other items, net(1)		80		81		58
Total other income (expense) – net		$	55	$	86	$	62

(1) Other items, net primarily consists of: change in tax indemnity, lease income, government grants, licensing and royalty income, and gains and losses related to derivatives for the year ended December 31, 2024; change in tax indemnity, lease income, licensing and royalty income, and gains and losses related to derivatives for the year ended December 31, 2023; and gains and losses related to derivatives and licensing and royalty income for the year ended December 31, 2022.